Grifols’ Innovation Strategy in the Plasma Medicine Space
XTalks
DECEMBER 12, 2023
Our pipeline, for example, includes a new class of recombinant antibodies. Within the next few months we’re expecting topline results from a Phase III clinical trial on a next-generation fibrinogen, an important plasma protein essential for blood clotting. The science is brilliant.
111 
Let's personalize your content